Clinical trial
An Exploratory Randomized Open-Label 2-Arm Comparison of Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec to Determine Optimum Basal Insulin Dosing Regimens in Type 1 Diabetes Mellitus Subjects
NCT03938740 is registered in ClinicalTrials.gov with Diasome Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Randomized Open-Label 2-Arm Comparison of Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec to Determine Optimum Basal Insulin Dosing Regimens in Type 1 Diabetes Mellitus Subjects
- Lead sponsor
- Diasome Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 18, 2019
- Completion date
- March 18, 2020
- Enrollment
- 61 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.